This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
by Zacks Equity Research
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes
by Zacks Equity Research
Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
by Zacks Equity Research
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.
Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab
by Zacks Equity Research
The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
by Zacks Equity Research
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
by Zacks Equity Research
Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.
Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
Merck (MRK) to Supply Coronavirus Treatment to U.S. Government
by Zacks Equity Research
Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.
Here's Why Lilly (LLY) Has Outperformed the Industry This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.
Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab
by Zacks Equity Research
The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US
by Zacks Equity Research
With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
by Zacks Equity Research
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA
by Zacks Equity Research
Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
by Zacks Equity Research
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
by Zacks Equity Research
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
by Zacks Equity Research
Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.